Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery
- 16 December 2010
- journal article
- case report
- Published by American Society of Hematology in Blood
- Vol. 116 (25), 5734-5737
- https://doi.org/10.1182/blood-2010-06-291906
Abstract
Clinical response to bypassing agents (BPAs) may vary between patients. Surgery is a particular situation, requiring effective hemostasis during the procedure and for several days postoperatively to obtain satisfactory wound healing. However, the optimal dose of BPA in different surgical situations has not been clearly established. We report here a prospective assessment of thrombin generation test (TGT) in monitoring the effectiveness of BPA during 10 elective invasive procedures performed in 6 patients with severe hemophilia and high-titer inhibitors. A standardized 3-step protocol was used in all cases to individually tailor BPA. Thrombin-generating capacity of patients increased after in vitro and ex vivo addition of BPA in a dose-dependent manner. Our results also showed a correlation between in vivo clinical response to BPA and thrombin-generating capacity. These data suggest that TGT may represent a surrogate marker for monitoring bypassing therapies in surgical situations.Keywords
This publication has 12 references indexed in Scilit:
- Tests of global haemostasis and their applications in bleeding disordersHaemophilia, 2010
- Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitorsHaemophilia, 2009
- Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasmaHaemophilia, 2008
- Use of the Thrombin Generation Test to Evaluate Response to Treatment With Recombinant Activated Factor VIISeminars in Hematology, 2008
- The use of FEIBA for surgery in patients with haemophilia and inhibitorsHaemophilia, 2006
- Platelet-dependent thrombography: a method for diagnostic laboratoriesBritish Journal of Haematology, 2006
- Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decisionHaemophilia, 2005
- Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and BThrombosis and Haemostasis, 2005
- Recombinant human factor VIIa (rFVIIa) can activate factor FIX on activated plateletsJournal of Thrombosis and Haemostasis, 2004
- Treatment of the Bleeding Inhibitor PatientSeminars in Thrombosis and Hemostasis, 2003